FDA Output April 2024
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in April 2024. Updated April 18, 2024.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in April 2024. Updated April 18, 2024.
Medtech Innovator cohort companies Lungpacer, Neurovalens, and Phagenesis advance the standard of care for a broad range of indications with neurostimulation technology.
CMS aims to identify diabetes endpoints. Excerpted from Pathways' Picks March 27: Dx Debate, Medicare Diabetes Endpoints, EU Expert Panels, and Global Picks.